Global Search | Novartis United States of America

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 683 results

Media Release / May 08, 2017

Novartis receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer
Media Release / Apr 27, 2017

Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the U.S. and Canada

Novartis and Amgen to co-commercialize AMG 334 (erenumab) in the U.S.; Novartis to gain exclusive rights in CanadaNovartis retains commercial rights in rest of world; Amgen retains commercial rights…
Media Release / Apr 27, 2017

Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the U.S. and Canada
Media Release / Apr 18, 2017

Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL

-- Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)-- R/r DLBCL, an…
Media Release / Apr 18, 2017

Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
Media Release / Mar 29, 2017

Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review

Priority review for investigational CTL019 (tisagenlecleucel-T), a novel therapy that is manufactured for each individual patient using their own T cellsNovartis made an early commitment to the…
Media Release / Mar 29, 2017

Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
Media Release / Mar 18, 2017

New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes

New post-hoc analysis of PARADIGM-HF data demonstrates Entresto lowered levels of HbA1c (a measure of glycemic control) by 0.26% vs. 0.16% for ACE-inhibitor enalapril in heart failure with reduced…
Media Release / Mar 18, 2017

New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
Media Release / Mar 06, 2017

Novartis' Cosentyx® shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause

- 94% of patients regained their PASI 75 response and the majority re-achieved their PASI 90 or 100 response after 16 weeks of Cosentyx 300 mg retreatment(1)- Patients may need to pause treatment due…

‹ Previous page
1
…
37
38
39
40
41
42
43
…
69
› Next page